Metex (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA synthesis. This limits the proliferation of rapidly dividing cells, including immune cells that drive inflammation and cancer cells that drive tumour growth.

The exact dose of Metex is determined by the prescribing clinician based on the specific indication, patient weight, renal function and treatment protocol. Dosage regimens are individualized and should follow the prescriber’s instructions.

Methotrexate is classified as Pregnancy Category X because it can cause severe fetal malformations and miscarriage. It is contraindicated in pregnancy and should be stopped well before conception. Breastfeeding is also not recommended while using methotrexate.

To place an order, submit an enquiry on the Metex product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with biologic agents such as TNF‑alpha inhibitors, methotrexate is a small‑molecule antimetabolite that is less expensive and can be combined with other drugs. However, it may have a broader side‑effect profile, especially concerning liver and bone‑marrow toxicity, requiring regular monitoring.

Metex should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Metex is supplied as a sterile injection for subcutaneous administration. It is typically injected into the fatty tissue of the abdomen or thigh using a pre‑filled syringe or vial, following aseptic technique and the prescriber’s dosing schedule.

The most serious risks include severe liver injury, pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, acute kidney failure, and life‑threatening infections. Patients should be monitored closely for signs of these complications.

Metex is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe liver or renal impairment, and those with active infections such as untreated tuberculosis. It should also be avoided in patients receiving live vaccines.